We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 24 for:    Recruiting, Not yet recruiting, Available Studies | "Hydrocephalus"

A Randomized Cross-over Study for Normal Pressure Hydrocephalus (ARCS NPH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01798641
Recruitment Status : Recruiting
First Posted : February 26, 2013
Last Update Posted : March 22, 2017
Sponsor:
Collaborators:
Information provided by (Responsible Party):

January 31, 2013
February 26, 2013
March 22, 2017
January 2013
August 2017   (Final data collection date for primary outcome measure)
  • Difference in Tinetti score on optimal vs. sub optimal drainage [ Time Frame: 6 week follow-up on treatment arms ]
    The Tinnetti tool test measures walking and balance.
  • Difference in Timed Up and Go (TUG) score on optimal vs. sub optimal drainage [ Time Frame: 6 week follow-up on treatment arm ]
    The TUG evaluation measures walking and balance.
  • Difference in MCV Gait Grade on optimal vs. sub optimal drainage [ Time Frame: 6 week follow-up at treatment arm ]
    The MCV gait grade evaluation measures balance and walking.
  • Difference in Kiefer score on optimal vs. sub optimal drainage [ Time Frame: 6 week follow-up on treatment arms ]
    The Kiefer is a modified clinical grading tool that measures the severity of your symptoms in five domains: gait/balance, mental, urinary function,headache, dizziness.
  • Difference in Kudo score on optimal vs. sub optimal drainage [ Time Frame: 6 week follow-up on treatment arms ]
    The Kudo tool measures your symptoms in three categories: cognitive (attention and memory), gait/balance and urinary function.
Same as current
Complete list of historical versions of study NCT01798641 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Randomized Cross-over Study for Normal Pressure Hydrocephalus
Efficacy of Shunt Surgery in Normal Pressure Hydrocephalus: a Randomized Cross-over Study
The goal of our study is to verify the effectiveness of the shunt and to identify the most sensitive criteria to select patients for surgery. The study is designed to assess improvement in walking and balance (gait), urinary function and memory after shunting. In addition, the study aims to identify the most accurate and sensitive tools to measure improvement for our patients.

Normal Pressure Hydrocephalus (NPH) causes memory loss, walking, and urinary difficulties. If NPH goes unidentified and untreated it can cause severe disability. The cause of this disease is poorly understood. It may involve damage caused by impaired blood flow in the brain.

The standard methods by which we diagnose patients who have symptoms of NPH are less accurate than desired. Many times patients remain undiagnosed or untreated while others receive treatment due to a false-positive diagnosis.

To treat NPH, a small tube called a 'shunt' can be surgically placed in the brain to drain cerebrospinal fluid (CSF) and help relieve symptoms. Currently, the reported response rates to shunting vary from 31% to 89%. Follow-up studies have shown that the shunts may not work long-term. This could be due to the natural history of the disease, development of other diseases, or due to a short term 'placebo effect' following the shunt placement surgery.

Our group is doing a study of patients with NPH. All participants in this study will have a shunt placed. These shunts are programmable and, once placed, may be opened or closed by the doctor. Programming the shunt does not require an additional surgical procedure. All study participants will be divided into two groups. One group will have their shunts open and draining. The other group will have their shunts closed (not draining). After 6 weeks, the groups will be switched. Those with open shunts will have them closed, and the group with closed, non-draining shunts, will have theirs opened. Participants will not know if their shunts are open (draining) or if they are closed (not draining). Study participants will be followed for two years. Any participants who develop recurrent, new or worsening symptoms will be taken off study and treated according to good medical practice.

The purpose of this study is to (a) look for symptom improvement in response to the draining shunt compared to the non-draining shunt (placebo affect), (b) find 'predictors' that will help doctors identify patients who will respond well to shunt placement, (c) monitor the long-term effects of these shunts, and (d) assess current diagnostic testing to see which methods are most accurate.

Eligibility Criteria:

Inclusion Criteria

  1. Age of Patients ( between 60 to 85 years old).
  2. Clinically suspected Idiopathic Normal Pressure Hydrocephalus (iNPH) with at least gait impairment.
  3. Informed consent from patient.

Exclusion Criteria

  1. Etiology for hydrocephalus other than iNPH.
  2. Patients not capable of providing an informed consent.
  3. History of intra-cerebral hemorrhage.
  4. Cardiac Pacemaker.
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Normal Pressure Hydrocephalus
Device: MIETHKE proGAV® / MIETHKE proSA®
The programmable shunt will be adjusted through the MIETHKE proGAV® / MIETHKE proSA® valve and crossed over at 6 weeks. The open shunt will be adjusted to be closed. The closed shunt will be adjusted to open.
  • Experimental: Open Shunt
    The programmable valve, MIETHKE proGAV® / MIETHKE proSA®, will be open at this time. The adjustment is done in the out-patient clinic.
    Intervention: Device: MIETHKE proGAV® / MIETHKE proSA®
  • Placebo Comparator: Closed Shunt
    The programmable valve, MIETHKE proGAV® / MIETHKE proSA®, will be closed during this time. The adjustment is done in the out-patient clinic.
    Intervention: Device: MIETHKE proGAV® / MIETHKE proSA®
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
48
August 2017
August 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age of Patients ( between 60 to 85 years old)
  • Clinically suspected Normal Pressure Hydrocephalus (NPH) with at least gait impairment
  • Informed consent from patient

Exclusion Criteria:

  • Etiology for hydrocephalus other than idiopathic normal pressure hydrocephalus
  • Patients not capable of providing an informed consent.
  • History of intra-cerebral hemorrhage
  • Cardiac Pacemaker
Sexes Eligible for Study: All
60 Years to 85 Years   (Adult, Senior)
No
Contact: Jennifer Lu 443-287-3648 hydrocephalus@jhmi.edu
Contact: Daniele Rigamonti, MD FACS 410-955-2259 hydrocephalus@jhmi.edu
United States
 
 
NCT01798641
NA_00042178
No
Not Provided
Not Provided
Johns Hopkins University
Johns Hopkins University
  • Aesculap, Inc.
  • Ohio State University
  • Rhode Island Hospital
  • Virginia Commonwealth University
  • Henry Ford Health System
Principal Investigator: Daniele Rigamonti, MD FACS Johns Hopkins University
Study Director: Jennifer Lu Johns Hopkins University
Johns Hopkins University
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP